Rubi Thapa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rubi Thapa has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gehanath Baral
Paropakar Maternity and Women’s Hospital, Kathmandu, Nepal
1 shared publication - Joseph Varon
The University of Houston, Houston, Texas, USA
1 shared publication - Munish Sharma
Pulmonary and Critical Care, Baylor Scott & White Medical Center - Temple, Temple, USA
1 shared publication - Rajiv Shah
Department of Obstetrics and Gynecology, Karnali Academy of Health Sciences, Jumla, Nepal
1 shared publication - Robin Khapung1 shared publication
- Sagarika Basnet
Department of Internal Medicine Kathmandu Medical College Kathmandu Nepal
1 shared publication
Latest Publications
- Open Access
- 10 January 2026
- Published by Karnali Academy of Health Sciences in Journal of Karnali Academy of Health Sciences
- Vol. 8 (3) , 23-26
Insight on patient profile undergoing caesarean delivery: a hospital based study in Karnali Academy of Health Sciences
Introduction: Cesarean section (CS) rates are rising globally, often exceeding World Health Organization recommendations. While well-documented in urban centers, data from remote, resource-limited regions such as Nepal’s Karnali Province are scarce. This study aims to determine the key maternal characteristics and clinical indications for CS at a tertiary hospital in a remote setting. Methods: This was a retrospective, cross-sectional study of all deliveries at Karnali Academy of Health Sciences between June 2023 and June 2024. Data on maternal demographics, obstetric history, and CS indications were collected from hospital maternity records. Descriptive statistics were used to analyze the data. Results: Among 801 deliveries, 180 were cesarean sections, yielding a CS rate of 22.5%. The mean maternal age was 24.75±4.92 years, and nulliparous women constituted the largest group (42.8%). Most CSs were emergency procedures (84%). The leading indications were previous CS (16.1%), breech presentation (13.9%), meconium-stained liquor (10.6%), and fetal distress (10.6%). Robson classification analysis identified women with a previous CS (Group 5) as the largest contributor to the overall rate (23.3%). Conclusion: The CS rate in this remote Nepalese hospital is elevated. The high proportion of emergency procedures and the prominence of previous CS as a primary indication highlight critical areas for intervention. To optimize CS use, targeted strategies such as promoting vaginal birth after cesarean and strengthening standardized intrapartum monitoring are urgently needed.
- 10 January 2026
- Published by Karnali Academy of Health Sciences in Journal of Karnali Academy of Health Sciences
- Vol. 8 (3) , 23-26
Open AccessInsight on patient profile undergoing caesarean delivery: a hospital based study in Karnali Academy of Health Sciences
Introduction: Cesarean section (CS) rates are rising globally, often exceeding World Health Organization recommendations. While well-documented in urban centers, data from remote, resource-limited regions such as Nepal’s Karnali Province are scarce. This study aims to determine the key maternal characteristics and clinical indications for CS at a tertiary hospital in a remote setting. Methods: This was a retrospective, cross-sectional study of all deliveries at Karnali Academy of Health Sciences between June 2023 and June 2024. Data on maternal demographics, obstetric history, and CS indications were collected from hospital maternity records. Descriptive statistics were used to analyze the data. Results: Among 801 deliveries, 180 were cesarean sections, yielding a CS rate of 22.5%. The mean maternal age was 24.75±4.92 years, and nulliparous women constituted the largest group (42.8%). Most CSs were emergency procedures (84%). The leading indications were previous CS (16.1%), breech presentation (13.9%), meconium-stained liquor (10.6%), and fetal distress (10.6%). Robson classification analysis identified women with a previous CS (Group 5) as the largest contributor to the overall rate (23.3%). Conclusion: The CS rate in this remote Nepalese hospital is elevated. The high proportion of emergency procedures and the prominence of previous CS as a primary indication highlight critical areas for intervention. To optimize CS use, targeted strategies such as promoting vaginal birth after cesarean and strengthening standardized intrapartum monitoring are urgently needed.
- Open Access
- 10 February 2025
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 19 (1)
Updates on Pulmonary Hypertension
Pulmonary Arterial Hypertension (PAH) is an uncommon condition with high mortality. It is an underrecognized condition both in developing and developed countries, especially in developing countries, due to a lack of advanced healthcare facilities and resources for timely diagnosis. More than half of the individuals diagnosed with PAH live less than five years after diagnosis. In recent years, tremendous advancements have been made in diagnostic and therapeutic strategies for PAH patients. Phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists, and prostacyclin inhibitors in various forms (oral, inhaled, intravenous, or subcutaneous) have been the cornerstone of medical treatment. Atrial septostomy, heart and lung transplant, balloon pulmonary angioplasty, and pulmonary thromboendarterectomy are existing therapeutic options currently available. There has been a continuous effort to introduce newer therapies to improve life expectancy and modify disease. Newer therapies have shown promising results but require future data to guarantee long-term safety and efficacy. We aim to discuss a few of these critical updates in the constantly evolving field of PAH.
- 10 February 2025
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 19 (1)
Open AccessUpdates on Pulmonary Hypertension
Pulmonary Arterial Hypertension (PAH) is an uncommon condition with high mortality. It is an underrecognized condition both in developing and developed countries, especially in developing countries, due to a lack of advanced healthcare facilities and resources for timely diagnosis. More than half of the individuals diagnosed with PAH live less than five years after diagnosis. In recent years, tremendous advancements have been made in diagnostic and therapeutic strategies for PAH patients. Phosphodiesterase 5 (PDE5) inhibitors, endothelin receptor antagonists, and prostacyclin inhibitors in various forms (oral, inhaled, intravenous, or subcutaneous) have been the cornerstone of medical treatment. Atrial septostomy, heart and lung transplant, balloon pulmonary angioplasty, and pulmonary thromboendarterectomy are existing therapeutic options currently available. There has been a continuous effort to introduce newer therapies to improve life expectancy and modify disease. Newer therapies have shown promising results but require future data to guarantee long-term safety and efficacy. We aim to discuss a few of these critical updates in the constantly evolving field of PAH.